(NaturalNews) In February of 2010, an article appeared in J Epidemiol Community Health
titled: "Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany" blatantly refers to converting cervical cancer from a oncological disease into an infectious disease. The article was written by Professor Martina Doren, with the Clinical Research Center of Women's Health at Charite-Universita tsmedizin in Berlin.
"For approximately two years now, cervical cancer has been "converted" from an oncological disease to an infectious disease, which is said to be preventable by and large by two vaccines licensed in many countries. However, human papillomavirus (HPV) vaccines differ from existing others, as the former target a condition which only in a minute fraction of infections will lead to serious consequences, but after a long(er) latency period. Furthermore, it should be kept in mind that in clinical trials, the quadrivalent vaccine was tested in fewer than 1200 girls 16 years and younger."
SaneVax Inc., wants to know the science behind the conversion.
In all her candor Professor Doren cited data as to what fraction of cervical intraepithelial lesions (CIN) grade 2 or worse and cancer incidence, respectively, are indeed prevented in young girls not infected with any HPV type prior immunization for periods beyond two years.
"In spring 2006, an analysis of vaccine efficacy against CIN 2+ due to any HPV type among subgroup of girls/women (per protocol population) for all four vaccine-relevant HPV
types showed an observed reduction of (only) 16.9% regarding these lesions3 (for a discussion of published efficacy data in Germany, see also Gerhardus et al)."
Dr. Doren continues with a concern the SaneVax Team has... that even though human papillomavirus passes through 90 percent of women in a two year time period, the HPV vaccines may be marketed as an ill-founded "magic bullet" just as HRT was pushed on unsuspecting, ill-informed menopausal women.
"Thus, the efficacy of the licensed vaccines to prevent cervical cancer
is unknown; in other words, it is unknown whether vaccinations are indeed a "magic bullet," a term also used recently to re-evaluate menopausal hormone therapy, the benefits of which were not "magic" after all. Perhaps the magic of female nature in this case is that most infections (approximately 90 percent) are dealt with very effectively and permanently in immunocompetent (young) women. Therefore, girls/women with HPV infections are highly unlikely to develop invasive cervical cancer
. This is crucial risk information not transported affirmatively by various parties actively promoting HPV vaccination."
In her closing statement, Dr. Doren states: "Thus, we are not able to appraise the contribution of HPV vaccines to decrease the burden of cervical cancer today in Germany."
Compare Dr. Doren's timely remarks and concerns to a statement made by Professor Raina MacIntyre, in a November 15, 2005 article titled: "Dr. Ian Frazer's excellent adventure."
"As to parental acceptance of vaccinating children against what is essentially a sexually transmitted infection, a lot will depend on how the vaccine
is marketed. If it is marketed as a cancer preventing vaccine, there won't be as much resistance."
So, if parents are wary of vaccinating their children against sexually transmitted infection - and if Cervarix and Gardasil are marketed as "cancer preventing vaccines," then, acceptance and uptake numbers might become more impressive. It appears to the SaneVax Team the magic bullet in this case is the conversion of cervical cancer into a sexually transmitted disease. It provided the perfect marketing strategy.
Too bad the science evidence does not back up the conversion.
Obviously, the public is seeing through the "magic bullet" concept. On November 23, 2010, the American Medical News
released an article with reference to the University of Maryland study recommending that 'counseling' helps women start and complete the HPV regimen. According to data released from the University of Maryland Medical Center, only 30 percent who begin the three-dose HPV vaccine series actually complete it. Between August 2006 and August 2010, 9,658 outpatient females ages nine to 26 were surveyed. The data showed that only 27.3 percent of the women received at least one dose of the HPV vaccine.
"Of those individuals, 39.1 percent got only a single dose and 30.1 percent received two doses. The remaining 30.8 percent completed the three-dose series.
The SaneVax Team objects to additional pressure placed on adolescents for administration of a potentially dangerous vaccine whose safety and efficacy has not been established outside of a clinical trial on "healthy adolescent girls," for strains of a virus not yet proven to cause cervical cancer.
Globally, researchers, doctors, educators, politicians and the public have seen through the HPV magic bullet marketing campaign. It is time for the pharmaceutical companies and the government to acknowledge the flaws in the scientific development of these vaccines and remove them from the market until their safety and efficacy has been proven and a causal relationship between HPV and cervical cancer has been firmly established.About the author:
THE SANE VAX MISSION is to promote Safe, Affordable, Necessary & Effective vaccines and vaccination practices through education and information. We believe in science-based medicine. Our primary goal is to provide the information necessary for you to make informed decisions regarding your health and well-being. We also provide referrals to helpful resources for those unfortunate enough to have experienced vaccine-related injuries.
We are demanding the HPV vaccines be taken off the market until an independent study on their safety and efficacy has been conducted. Until then, we are committing our efforts to an educational media campaign to alert the public about the dangers of the HPV vaccines.
SANE Vax, Inc. is involved in the ground-breaking production of the One More Girl Documentary which will premier in 2012. Please join our cause by contributing to this project by contacting Ryan Richardson, Producer at firstname.lastname@example.org.
For more information, please visit our site at http://sanevax.org/